Docetaxel-estramustine in localized high-risk prostate cancer: Results of the French Genitourinary Tumor Group GETUG 12 phase III trial.

Tumor Group ◽

Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Abdenour Nabid, Nathalie Carrier, André-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432–31

European Urology ◽

10.1016/j.eururo.2018.10.029 ◽

2019 ◽

Vol 75 (3) ◽

pp. e63

Author(s):

Abdenour Nabid ◽

Luis Souhami

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Androgen Deprivation ◽

Phase Iii ◽

Phase Iii Trial ◽

Letter To The Editor ◽

A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high risk prostate cancer: Results of SPCG12.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.5001 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 5001-5001 ◽

Cited By ~ 5

Author(s):

Goran Ahlgren ◽

Per Flodgren ◽

Teuvo L. J. Tammela ◽

Pirkko Kellokumpu-Lehtinen ◽

Michael Borre ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Radical Prostatectomy ◽

Phase Iii ◽

Phase Iii Trial ◽

A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.5000 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 5000-5000 ◽

Cited By ~ 9

Author(s):

Pirkko-Liisa Irmeli Kellokumpu-Lehtinen ◽

Marie Hjälm-Eriksson ◽

Lennart Astrom ◽

Timo Marttila ◽

Camilla Thellenberg-Karlsson ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Phase Iii ◽

Radical Radiotherapy ◽

Phase Iii Trial ◽

Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial

European Urology ◽

10.1016/j.eururo.2018.06.018 ◽

2018 ◽

Vol 74 (4) ◽

pp. 432-441 ◽

Cited By ~ 54

Author(s):

Abdenour Nabid ◽

Nathalie Carrier ◽

André-Guy Martin ◽

Jean-Paul Bahary ◽

Céline Lemaire ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Androgen Deprivation ◽

Phase Iii ◽

Phase Iii Trial ◽

Re: Abdenour Nabid, Nathalie Carrier, André-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432–31

European Urology ◽

10.1016/j.eururo.2018.10.030 ◽

2019 ◽

Vol 75 (3) ◽

pp. e61-e62 ◽

Cited By ~ 2

Author(s):

Pirus Ghadjar ◽

Thomas Wiegel

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Androgen Deprivation ◽

Phase Iii ◽

Phase Iii Trial ◽

MP46-10 PROSPECTIVE RANDOMIZED CLINICAL PHASE-III TRIAL OF LIMITED VS EXTENDED PELVIC LYMPHADENECTOMY IN INTERMEDIATE AND HIGH RISK PROSTATE CANCER (PCA) – FIRST DESCRIPTIVE RESULTS (SEAL, AUO AP 55/09)

The Journal of Urology ◽

10.1016/j.juro.2014.02.1443 ◽

2014 ◽

Vol 191 (4S) ◽

Author(s):

Julia Schwerfeld-Bohr ◽

Susanne Krege ◽

Markus Graefen ◽

Jörn Witt ◽

Axel Heidenreich

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Pelvic Lymphadenectomy ◽

Phase Iii ◽

Phase Iii Trial ◽

Clinical Phase ◽

Outcomes Comparison Using PSA Cut-Off Values Of 0.1 Or 0.2 Ng/Ml At 6 Months In Localized High-Risk Prostate Cancer Treated With Androgen Deprivation Therapy And Radiotherapy: Prospective Data From A Phase III Trial

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2020.07.416 ◽

2020 ◽

Vol 108 (3) ◽

pp. e855

Author(s):

A. Nabid ◽

M.P. Garant ◽

F. Cury ◽

A.G. Martin ◽

J.P. Bahary ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Androgen Deprivation ◽

Phase Iii ◽

Prospective Data ◽

Phase Iii Trial ◽

Faculty Opinions recommendation of Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.733593446.793548087 ◽

2018 ◽

Author(s):

Michael Glode

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Androgen Deprivation ◽

Phase Iii ◽

Phase Iii Trial ◽

Does nadir testosterone at the end of long term androgen deprivation therapy predict outcomes in high risk prostate cancer? Data from a phase III trial

European Urology Supplements ◽

10.1016/s1569-9056(17)30126-4 ◽

2017 ◽

Vol 16 (3) ◽

pp. e96-e97

Author(s):

A. Nabid ◽

M.-P. Garant ◽

A.-G. Martin ◽

L. Souhami ◽

M. Duclos ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Androgen Deprivation ◽

Phase Iii ◽

Phase Iii Trial ◽

Cancer Data ◽

Phase III Multi-Institutional Trial of Adjuvant Chemotherapy With Paclitaxel, Estramustine, and Oral Etoposide Combined With Long-Term Androgen Suppression Therapy and Radiotherapy Versus Long-Term Androgen Suppression Plus Radiotherapy Alone for High-Risk Prostate Cancer: Preliminary Toxicity Analysis of RTOG 99-02

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2008.05.020 ◽

2009 ◽

Vol 73 (3) ◽

pp. 672-678 ◽

Cited By ~ 52

Author(s):

Seth A. Rosenthal ◽

Kyoungwha Bae ◽

Kenneth J. Pienta ◽

Mark L. Sobczak ◽

Sucha O. Asbell ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Phase Iii ◽

Oral Etoposide ◽

Risk Prostate Cancer ◽

Toxicity Analysis ◽

Radiotherapy Alone ◽

Androgen Suppression